Press Releases

Date Title  
Toggle Summary Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health Science, Demonstrating Shared Commitment to Advancing Food Allergy Therapeutics
— Nestlé Health Science to Make Investment through the Purchase of Nearly 7.6 Million Shares of Aimmune Stock at $19.20 per Share — — Companies Enter into Strategic Collaboration Agreement Designed to Enable the Successful Development and Commercialization of Innovative Food Allergy Therapies — —
Toggle Summary Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy
— PALISADE Completed in 2017; Topline Results Anticipated in February — — Late-Breaking Abstract Presentation at the 2018 American Academy of Allergy , Asthma & Immunology–World Allergy Organization Joint Congress in March — — PALISADE Follow-On Study, ARC004, Fully Enrolled — — RAMSES Real-World
Toggle Summary Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy
— Phase 2 Clinical Trial Will Explore AR101 Treatment with Adjunctive Dupilumab in Peanut-Allergic Patients — — Trial Design Will Test Potential to Achieve Sustained Unresponsiveness to Peanut Following Treatment — — Conference Call Today at 8:30 a.m. Eastern Time / 5:30 a.m.
Toggle Summary Aimmune Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 11, 2015-- Aimmune Therapeutics, Inc. , today announced the closing of its initial public offering of 11,499,999 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions, which includes the
Toggle Summary Aimmune Therapeutics Announces COO Transition
— COO Howard Raff to Retire from Leadership Position to Focus on Future Pipeline Development — — Aimmune Builds Clinical Team with Key Allergist / Immunologist Hires — BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 9, 2015-- Aimmune Therapeutics, Inc.
Toggle Summary Aimmune Therapeutics Announces Financial Results for the Third Quarter 2015
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 4, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced financial results for the third quarter and nine months ended September 30, 2015 .
Toggle Summary Aimmune Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update
BRISBANE, Calif. --(BUSINESS WIRE)--May 16, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced financial results for the first
Toggle Summary Aimmune Therapeutics Announces First Quarter 2017 Financial Results
BRISBANE, Calif. --(BUSINESS WIRE)--May 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced financial results for first quarter
Toggle Summary Aimmune Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
─ Company Began 2016 with Approximately $200 Million in Cash and Investments and Its Phase 3 PALISADE Trial Underway for Peanut Allergic Patients ─ ─ Late-Breaker Presentation on New AR101 Phase 2 Data This Sunday at AAAAI ─ ─ Conference Call and Webcast Today at 5 p.m. Eastern Time / 2 p.m.
Toggle Summary Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
— Company Began 2017 with Approximately $283 Million in Cash and Investments, Sufficient to Support Current Development Plans through Regulatory Submissions — — Conference Call and Webcast Today at 8:00 a.m. ET — BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 15, 2017-- Aimmune Therapeutics, Inc.